27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Studies have shown that multimorbidity may be associated with the Alzheimer's disease (AD) stages, but it has not been fully characterized in patients without dementia. 5 key findings →
Participants: 1,402 Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-based biomarkers offer strong potential to revolutionize diagnosis, trial enrolment and treatment monitoring in Alzheimer's disease (AD). 3 key findings →
Participants: 962 Evidence: low
Full summary, score breakdown and related studies → Original source
We obtained a predictive accuracy of 0.71 (95 % CI [0.59, 0.84]) with an AUC of 0.69 in the HRS test dataset and got an accuracy of 0.62 (95 % CI [0.56, 0.68]) with an AUC of 0.63 in the ROSMAP dataset. 3 key findings →
Participants: 234 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cerebrovascular dysregulation is a hallmark of Alzheimer's disease (AD), but the changes that occur in specific cell types have not been fully characterized. 1 key finding →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source
Fusion of all five data modalities (n = 111) yielded two subtypes (n S1 = 53, n S2 = 58), which were nominally associated with diffuse amyloid plaques; however, this effect was not significant after correction for multiple testing. 5 key findings →
Participants: 111 Evidence: low
Full summary, score breakdown and related studies → Original source
GMM-based cutoffs classified less subjects as T+, mainly in the A- CN (<3.4% vs >28.5%) and A+ CN (<14.5% vs >42.9%) groups and showed higher agreement with visual rating (ICC=0.91 vs ICC<0.62) than published cutoffs. 3 key findings →
Participants: 269 Evidence: low
Full summary, score breakdown and related studies → Original source
The objective of this study was to evaluate the relation of metformin with change in cognition and brain pathology. 2 key findings →
Participants: 3,029 Evidence: low
Full summary, score breakdown and related studies → Original source
CR varied across five cognitive assessments and was greater in female participants, associated with longer survival, and weakly associated with educational attainment or APOE ε4 allele. 5 key findings →
Participants: 844 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Bivariate analyses indicated that nonmetro dementia caregivers were less racially/ethnically diverse (82.7% White, non-Hispanic) and more were spouses/partners (20.2%) than their metro counterparts (66.6% White, non-Hispanic; 13.3% spouses/partners). 5 key findings →
Participants: 808 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma GFAP effectively distinguished AD dementia from multiple neurodegenerative diseases, gradually increased across the AD continuum, predicted the individual risk of AD progression, and strongly correlated with AD CSF/neuroimaging biomarkers. 2 key findings →
Participants: 818 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is one of the most commonly diagnosed cases of senile dementia in the world. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Both FC-BAG and S-BAG are elevated in CI participants. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A location dynamics model and ADRD-focused future directions are offered for guiding rural practitioners, researchers, and policymakers in mitigating rural disparities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
According to the World Health Organization (WHO), dementia is the seventh leading reason of death among all illnesses and one of the leading causes of disability among the world's elderly people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The AD drug development pipeline is advancing agents directed at a variety of target processes. 1 key finding →
Design: clinical trial Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Macrophages are central orchestrators of the tissue response to injury, with distinct macrophage activation states playing key roles in fibrosis progression and resolution. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
TREM2 is an innate immune receptor expressed by microglia in the adult brain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMH) correlate with Alzheimer disease (AD) biomarkers cross-sectionally and modulate AD pathogenesis. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Altered levels of kynurenines in blood and cerebrospinal fluid (CSF) have been reported in Alzheimer's disease (AD). 4 key findings →
Design: cohort study Participants: 138 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The 21-point Brain Care Score (BCS) was developed through a modified Delphi process in partnership with practitioners and patients to promote behavior changes and lifestyle choices in order to sustainably reduce the risk of dementia and stroke. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lenore Ackerman *Correspondence: David Geffen School of Medicine, 10833 Le Conte Ave, Box 951738, Los Angeles, CA 90095-1738 telephone: 310-794-0206; E-mail Address: [email protected] https://orcid.org/0000-0003-4192-7649 Department of Urology and Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California View All Author Informationhttps://doi.org/10.1097/JU.0000000000003430AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Overactive bladder, including symptoms of increased urinary frequency, urgency, and incontinence, is more prevalent than diabetes, affecting 1 in 6 adults in the United States.1,2 Occurring more commonly among women and older adults, untreated overactive bladder is associated with reduced quality of life, increased incidence of depression and anxiety, increased risk of experiencing falls/fractures, and increased institutionalization. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We examined factors associated with self-reported medication nonadherence in well-characterized community-based cohort of older adults. 5 key findings →
Design: cohort study Participants: 5,164 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Evidence shows that ADAM10 levels are altered in platelets, plasma, serum, and CSF of individuals with AD. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. 1 key finding →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →